Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective

Ali A Abdeen, Turgay Ayer, Francesca Lim, Stephanie Shue, Chin Hur · 2026

Read Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective by Ali A Abdeen, Turgay Ayer, Francesca Lim, Stephanie Shue, Chin Hur (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218183.txt.

Description

Ali A. Abdeen and co-authors calculate what a fair price would be for the drug tislelizumab in advanced esophageal cancer, in a 2026 Markov modelling study from a US payer perspective. Adding tislelizumab to chemotherapy extends life in squamous cell cancer of the esophagus, following the RATIONALE-306 trial design. Whether the benefit justifies the price depends on the value a health system assigns to a year of good-quality life.

The three-state model followed patients over a lifetime, comparing tislelizumab plus chemotherapy against chemotherapy alone, with a second-line drug in both arms. The combination gained 0.543 quality-adjusted life years and 0.837 life years over chemotherapy alone. At willingness-to-pay thresholds between 50,000 and 200,000 dollars per quality-adjusted life year, the price came out between 1,575 and 7,160 dollars per treatment cycle. Sensitivity analyses kept the prices stable, and the authors offer the range to guide coverage decisions and price negotiations.

Catalog record

CREATORAli A Abdeen, Turgay Ayer, Francesca Lim, Stephanie Shue, Chin Hur
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13218183

Browse the full library · About the Tower of Babel